URL Insurance Group.
Medicare Offerings

Update: Opioid Prescription Policy

 

The opioid addiction epidemic is one of America’s foremost health crises. According to the most recent statistics from the Centers for Disease Control and Prevention (CDC), opioids kill more than 33,000 people annually, and opioid abuse/overdose is considered a leading cause of shortened life expectancy in the U.S. 

The nation’s opioid epidemic reflects a complex set of circumstances. The pattern of opioid prescription—including dose and duration—and risk factors of age, gender, and condition are major determinants of whether a patient becomes dependent.  

In response to this growing crisis, Capital BlueCross has developed a comprehensive strategy to ensure safer drug use in our network including changes to our prescription drug formulary. We continue to notify all impacted members of the modified commercial (not Medicare) formulary changes:

  • Opioid prescriptions have new quantity level limits (QLLs) and daily dosage limits.
  • These limits are in effect for off-exchange members and will apply to exchange members effective January 1, 2018.
  • Prior authorization for long-acting or extended release opioid preparations is required.
  • Prescriber justification for non-cancer and non-terminal conditions will be reviewed to assess medical necessity.
  • Prior authorization is now required for oral fentanyl, methadone, and medication-assisted treatments (MATs)—namely Suboxone, Bunavail, Zubsolv, buprenorphine, buprenorphine/naloxone, and immediate-release sublingual or mucosal absorption preparations.

 

Opioid Prescription FAQs

 

  1. Can a member get additional quantities of medication above the new limits to reflect the original prescription?  Possibly, when the member’s doctor completes a QLL review.  If approved, the approval for the additional number of medications will be input into CVS’ Caremark Pharmacy system to allow the pharmacy to fill the extra supply.
  2. Can a member and/or provider appeal to allow up to the original quantity of medication on his or her prescription?  Yes, the member has appeal rights. Proper appeal documentation, medical records, and/or letters of medical necessity and diagnosis can be sent to our pharmacy appeals area. Note: There are no guarantees of the outcome of the appeal; however, the pharmacy appeals department will mail the letter to the member and if necessary, contact the member for further explanation.
  3. Was this formulary change a Capital BlueCross decision or a federal- or state- imposed change?  The over-utilization of opioids and associated deaths have reached epidemic proportions. As a result, federal, state, and local authorities have partnered to ensure judicious use and monitoring of these medication quantities. As part of this initiative, payer organizations like Capital BlueCross are able to utilize data that will identify potentially harmful doses and quantities which warrant further review by a qualified health care professional.
  4. May a member purchase medication outside of the insurance restrictions?  Yes, a member with a valid prescription from his or her doctor can fill all or the remainder of his or her prescription outside of the insurance quantity limits.
  5. If a member purchases medication outside the limits of the insurance restrictions, can he or she file a paper claim for reimbursement?  1) If the script was outright filled outside the insurance restriction, then a member can file a paper claim; however, the only level of reimbursement will be up to the new restricted limit. 2) If the member fills the script for the new quantity level and his or her doctor does a QLL for an additional amount, then any amount prescribed over the new limits will not be eligible for reimbursement because the maximum benefit limit has already been obtained.

 

 

Survey Reminder

 

We're committed to making this newsletter valuable to you and the way you do business.

If you haven't already, let us know how we're doing by completing this quick survey:

 

 

New Payment Address

 

We now have one consolidated mailing address for all segments:

 

First Class Mail
Payment Processing
PO Box 371482
Pittsburgh, PA 15250-7482

 

Overnight Courier
Payment Processing
Attn:  371482
500 Ross St. 154-0470
Pittsburgh, PA 15262-0001

 

 

Changes to Group Application

 

Several changes have been made to the Application for Group Benefits (C-70), available on your online producer portal. 

The updated application should now be used and is required for January 1, 2018 effective dates and beyond. No exceptions will be made for use of older applications due to PID filing and legal language updates. All versions of the previous form that may have been saved electronically or in paper form must be destroyed. 

Specific changes include: 

  • The form name submitted to the PID has been updated.
  • The group policy maker signature section has been replaced by an authorized group signature section, including language about authorized group representatives. Producers cannot sign this section. 
  • A Capital BlueCross representative signature is no longer required, and that section has been removed. 
  • The domestic partner question has been removed. All 2018 groups will be set up to allow domestic partner coverage with no rate impact to groups. It is up to group administrators to determine company policies. 
  • Groups with Capital BlueCross coverage within the past 12 months who were terminated delinquent are now required to pay their past due balance prior to new setup. This is effective for past review, beginning with groups applying for January 1, 2018 effective dates.

 

 

 

Capital BlueCross is an independent licensee of the BlueCross BlueShield Association serving 21 counties in Central Pennsylvania and the Lehigh Valley. Communications issued by Capital BlueCross in its capacity as administrator of programs. This is an advertisement.
View in Browser
2500 Elmerton Avenue, Harrisburg PA | capbluecross.com | © 2017 Capital BlueCross All Rights Reserved. 
Nondiscrimination and Foreign Language Assistance Notice | Unsubscribe?